Layer 04 · how the doses are expressed
BPC-157 Dosage as the Research Literature Records It
Per-kilogram animal-model figures, the under-30-minute clearance, the routes studied, and the oral-stability question — research context, never a usage instruction.
How BPC-157 doses are expressed in the research literature
BPC-157 dosage in the published work is expressed per body weight, in animals, and this page reports those figures as research context — not as guidance for any person. Rodent studies most often use figures around 10 microg/kg and 10 ng/kg, and some tendon work goes as low as 10 pg per rat [1]. Gastric-ulcer cytoprotection was studied at 400 ng/kg and 800 ng/kg [4]. The three human pilots used much larger absolute amounts by very different routes: 10 mg then 20 mg by intravenous infusion in the safety pilot [9], and 10 mg intravesically in the interstitial-cystitis study [11].
Those numbers do not convert into a human regimen, and nothing here should be read as one. They are the doses administered to specific species by specific routes in specific studies. The site states no recommended dose, frequency, or duration for people.
How long should I stay on BPC-157?
There is no validated human duration. Animal studies vary by model — tendon and muscle work runs days to weeks with once-daily dosing [1][5] — and none of that establishes a human course. This is research-context information, not a usage recommendation.
What happens when you stop taking BPC-157?
No withdrawal or discontinuation effects are characterized in humans, because no long-term human studies exist. The published record contains no controlled data on stopping, so any account of a stop effect would be speculation.
BPC-157 half-life and clearance
BPC-157 has an elimination half-life under 30 minutes, reported in the 2022 rat and dog pharmacokinetic study across intravenous and intramuscular routes [2]. The same work found linear pharmacokinetics, intramuscular bioavailability around 14-19% in rats and 45-51% in dogs, rapid breakdown into small peptide fragments that join normal amino-acid metabolism, and excretion through urine and bile.
A sub-30-minute half-life is short for a molecule credited with multi-week repair effects, which is why the literature leans toward a triggered or local signaling action rather than sustained plasma exposure. The clearance figure is the firmest pharmacokinetic datum in the BPC-157 record.
Oral and peroral BPC-157: the stability question
BPC-157 is termed a stable gastric pentadecapeptide because it is reported stable in human gastric juice, and that stability is the entire reason oral and peroral routes draw interest [7]. Rodent gastrointestinal studies use intragastric and peroral administration. But formal human oral pharmacokinetics have not been established, so the jump from "survives gastric juice in testing" to "works taken by mouth in people" is unproven.
The routes studied across the literature are intraperitoneal (most common in rodent work), intramuscular, intragastric/peroral, local or intra-lesional, intravenous (human pilot), intravesical (human cystitis pilot), and intra-articular (human knee-pain pilot). Storage and reconstitution practices discussed online are research-handling conventions, not validated clinical protocols.
Can BPC-157 be taken orally?
It is called a stable gastric pentadecapeptide because it is reported stable in gastric juice, which motivates oral interest [7]. But formal human oral pharmacokinetics are not established, so oral administration in people is not a validated route.
Does oral BPC-157 work?
Rodent gastrointestinal studies use intragastric and peroral routes, but there is no human oral-efficacy trial and no validated human oral pharmacokinetics [7]. Oral effectiveness in people is therefore unproven, regardless of the stability framing.